IDXX

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 15% year-over-year, driven by a 16% increase in VSG revenue and a 12% increase in FED revenue.
• Profitability: Net income nearly doubled to $7.3 million, supported by improved gross margins and a lower effective tax rate (38% vs. 39%).
• Cash Flow Deterioration: Operating cash flow turned negative ($1.7 million used) compared to $8.7 million provided in the prior year. This was primarily due to a $14.8 million decrease in accounts payable and a $10.0 million increase in accounts receivable.
• Expense Increases: R&D expenses rose 36% ($1.9 million increase) due to the inclusion of Blue Ridge Pharmaceuticals. Sales and marketing expenses decreased as a percentage of revenue (17% vs. 21%) due to prior workforce reductions.
• Acquisitions: The company acquired the Phoenix Veterinary Laboratory business in March 1999 for $1.3 million cash and a note.

Outlook, Risks, and Contingencies

• Liquidity: Management believes current cash and short-term investments ($124.3 million) are sufficient to fund operations for the foreseeable future.
• Legal Proceedings:
  • Patent Litigation: Synbiotics Corporation filed a suit regarding canine heartworm diagnostic patents; the suit was dismissed without prejudice in April 1999 but may be refiled. A significant portion of revenue relies on these products.
  • Antitrust: CDC Technologies is appealing a summary judgment ruling regarding antitrust violations related to hematology product distribution.
  • Contract Disputes: SA Scientific, Inc. is seeking up to $6.5 million in damages for alleged breach of contract.
• Year 2000 (Y2K): The company believes its internal systems are Y2K ready. However, the VetTest(R) clinical chemistry analyzer requires a software update to properly display dates after January 1, 2000. The company estimates Y2K costs will not be material.
• Future Risks: Risks include intense competition, reliance on proprietary technology, supply chain dependencies on single-source vendors, and regulatory hurdles in international markets.

Investor Verification Checklist

• Verify the status of the Synbiotics patent litigation and potential re-filing, given the revenue exposure to canine heartworm products.
• Monitor the accounts receivable collection trends, as the $10 million increase contributed significantly to negative operating cash flow.
• Assess the integration progress and financial performance of the Blue Ridge Pharmaceuticals acquisition, which drove R&D expense increases.
• Confirm the timeline for the VetTest(R) Y2K software update distribution to customers.
• Review the appeal status of the CDC Technologies antitrust case.